More Acrux Limited news
Acrux LimitedASX: ACR

Acrux confirms patent challenge

Jun 7, 2021 at 10:53 PM EDT · Issued by Acrux Limited

Filed with ASX · Jun 7, 2021 at 10:53 PM EDT

On 6ix: 6ix.com/news/acrux-confirms-patent-challenge

Acrux Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Acrux Limited on 6ix

Story so far

  • Acruxs fourth generic dossier accepted by FDA for reviewApr 15, 2021
  • Acrux Receives FDA Approval - Generic Testosterone SolutionJan 12, 2021
  • Jublia Patent Litigation SettlementApr 3, 2019

Earlier from Acrux

  • Acruxs fourth generic dossier accepted by FDA for reviewApr 15, 2021
  • Acrux Investor PresentationFeb 24, 2021
  • Appendix 4D and Half Year Accounts - for the 31 Dec acFeb 24, 2021
  • Share Purchase Plan Closes OversubscribedFeb 2, 2021
  • Acrux Receives FDA Approval - Generic Testosterone SolutionJan 11, 2021

Later from Acrux

  • Acrux Receives FDA Approval - Generic Efinaconazole SolutionJun 22, 2021
  • Acrux receives third FDA ANDA approvalJul 27, 2021
  • Appendix 4E and Financial ReportAug 25, 2021
  • US Launch - Testosterone Topical SolutionAug 25, 2021
  • Acrux Investor Presentation - September 2021Sep 1, 2021
All Acrux news releases↗

Follow Acrux into a list and get an email when it puts out news.

Follow Acrux
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer